Earnings Summary

Mersana Therapeutics Inc’s revenue fell -27.14% since last year same period to $10.7Mn in the Q4 2023. On a quarterly growth basis, Mersana Therapeutics Inc has generated 39.01% jump in its revenue since last 3-months.

Mersana Therapeutics Inc’s net profit jumped 57.41% since last year same period to $-19.54Mn in the Q4 2023. On a quarterly growth basis, Mersana Therapeutics Inc has generated 53.08% jump in its net profits since last 3-months.

Mersana Therapeutics Inc’s net profit margin jumped 41.54% since last year same period to -182.64% in the Q4 2023. On a quarterly growth basis, Mersana Therapeutics Inc has generated 66.25% jump in its net profit margins since last 3-months.

Mersana Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.18 - a -12.5% fall from last quarter’s estimates.

Mersana Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.18.

Mersana Therapeutics Inc’s earning per share (EPS) jumped 63.64% since last year same period to -0.16 in the Q4 2023. This indicates that the Mersana Therapeutics Inc has generated 63.64% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Mersana Therapeutics Inc’s return on assets (ROA) stands at -0.38.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Mersana Therapeutics Inc’s return on equity (ROE) stands at -2.66.